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Abstract
Endometriosis is a chronic, inflammatory disease characterized by the growth of endometrial 
tissue in aberrant locations outside the uterus. Neo-angiogenesis or establishment of new blood 
supply is one of the fundamental requirements of endometriotic lesion survival in the peritoneal 
cavity. IL-17A is emerging as a potent angiogenic and pro-inflammatory cytokine involved in the 
pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis and 
psoriasis. However, sparse information is available in the context of endometriosis. In this study, 
we demonstrate the potential importance of IL-17A in the pathogenesis and pathophysiology of 
endometriosis. The data show a differential expression of IL-17A in human ectopic endometriotic 
lesions and matched eutopic endometrium from women with endometriosis. Importantly, surgical 
removal of lesions resulted in significantly reduced plasma IL-17A concentrations. 
Immunohistochemistry revealed localization of IL-17A primarily in the stroma of matched ectopic 
and eutopic tissue samples. In vitro stimulation of endometrial epithelial carcinoma cells, Ishikawa 
cells and human umbilical vein endothelial cells with IL-17A revealed significant increase in 
angiogenic (VEGF, IL-8), pro-inflammatory (IL-6, IL-1β) and chemotactic cytokines (G-CSF, 
CXCL12, CXCL1, CX3CL1). Furthermore, IL-17A promoted tubulogenesis of HUVECs plated 
on matrigel in a dose-dependent manner. Thus we provide the first evidence that endometriotic 
lesions produce IL-17A and that the removal of the lesion via laparoscopic surgery leads to the 
significant reduction in the systemic levels of IL-17A. Taken together, our data shows a likely 
important role of IL-17A in promoting angiogenesis and pro-inflammatory environment in the 
peritoneal cavity for the establishment and maintenance of endometriosis lesions.
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Introduction
Endometriosis, one of the most prevalent causes of hysterectomy, infertility and chronic 
pelvic pain (1), is characterized by the growth of endometrial tissue at ectopic sites, 
including the peritoneal cavity. Among multiple factors involved in the complex 
pathophysiology of this disease (2), both a pro-inflammatory peritoneal environment and 
active neo-angiogenesis at the site of lesion development are thought to be integral to 
endometriotic lesion establishment and persistence. This notion is supported with the 
effectiveness of anti-inflammatory and anti-angiogenic drugs in minimizing pain and lesion 
size in mice and humans (3–5). Theorized to originate from menstrual material normally 
shed into the peritoneal cavity through the patent fallopian tube (6), the endometrial 
fragments, only in some women, initiate inflammatory response associated with tissue 
damage (7). This leads to the recruitment and activation of neutrophils and macrophages (8), 
which secrete and increase the concentrations of chemotactic and angiogenic cytokines such 
as CCL11 (9) and VEGF (10) in the peritoneal fluid. Indeed, the immune system of women 
who develop endometriosis is postulated to be abnormal, and the atypical activation of 
macrophages and subsequent recruitment of neutrophils (8), dendritic cells (11), T helper 
(12) and natural killer (NK) cells are suggested to play a crucial role in the pathogenesis of 
endometriosis (13, 14).
Interleukin (IL)-17A, a cytokine that was once believed to be primarily produced by T 
helper 17 (Th17) cells, is the most studied cytokine among the family of IL-17 cytokines. 
Since its discovery as a pro-inflammatory mediator (15), IL-17A has been recognized in its 
critical role in the promotion of disease progression and pathogenesis of autoimmune 
diseases (16). Furthermore, expression of IL-17A is associated with the pathogenesis of a 
variety of tumors, where it has been documented to exhibit both tumorigenic and anti-tumor 
effects depending on the tumor microenvironment (17). IL-17A mediates its action by 
binding to a heterodimeric complex of receptor composed of IL-17RA and IL-17RC for 
downstream cell signaling (18). Early in its discovery, majority of its production was 
thought to originate from Th17 cells; however further investigations have documented the 
expression of IL-17A from innate immune cells such as γδT (19–21), NK (22), neutrophils 
(16, 23) as well as mast cells (24), adding complexity to our understanding of the pleiotropic 
functions of this cytokine.
The pro-inflammatory nature of IL-17A was recognized in a seminal experiment conducted 
by Fossiez et al. (15) where rheumatoid synovial fibroblasts produced IL-6, IL-8, G-CSF 
and PGE2 in response to human recombinant IL-17A treatment. This effect was promptly 
abolished with the addition of anti-IL-17A monoclonal antibody. Since then, IL-17A has 
been extensively linked to the pathogenesis of chronic inflammatory diseases including 
rheumatoid arthritis and psoriasis (25). In addition, IL-17A promotes vascular remodeling of 
the airways in the mouse model of asthma via the recruitment of endothelial progenitor cells 
Ahn et al. Page 2













to the allergen exposed airway (26). Furthermore, it confers tumor resistance to anti-VEGF 
therapy via induction and secretion of angiogenic and inflammatory factors such as Bv8 and 
IL-6 from tumor stromal cells (27). Recently, IL-17A was demonstrated to be involved in 
the promotion of ovarian cancer growth in mice via up-regulation of pro-angiogenic and 
inflammatory mediators from small peritoneal macrophages (21). Despite much 
advancement made in understanding the role of IL-17A in other disease pathogenesis, little 
is known regarding its role in endometriosis. So far, IL-17A has been documented to induce 
the production of IL-8 and COX-2 from endometriotic stromal cells, in addition to 
promoting proliferation of the cells (28). Furthermore, IL-17A concentration in the 
peritoneal fluid of women with endometriosis correlated with endometriosis disease severity 
and infertility of the patients (29). These reports clearly point towards the potential 
involvement of IL-17A in the pathogenesis of endometriosis that warrants further 
investigation.
Endometriosis is a chronic disease characterized by the elevation of pro-inflammatory 
cytokines in the peritoneal fluid. Concentrations of cytokines such as TNF-α, IL-6 and IL-8 
are increased in the peritoneal fluid and are augmented in production from activated 
peritoneal macrophages, which primarily contribute to the inflammatory milieu associated 
with pathogenesis of the disease. Furthermore, secretory factors from immune cells mediate 
vascularization of endometriotic lesions through both neo-angiogenesis stimulated by VEGF 
(30) and de novo vasculogenesis at the site of implantation through recruitment of bone-
marrow derived endothelial progenitor cells (EPCs) (31, 32). Emerging evidences from 
cancer and autoimmune literature suggest that IL-17A contributes to the neo-angiogenesis 
and perpetuates inflammatory responses (25, 33), but there are few reports investigating the 
role of IL-17A in the pathogenesis of endometriosis. Here we show that endometriotic 
lesions are capable of producing variable amounts of IL-17A, depending on the disease 
severity, and that systemic concentrations of IL-17A drop significantly in endometriosis 
patients after surgical removal of endometriotic lesions. In addition, we document the effects 
of recombinant IL-17A on the induction of pro-angiogenic, chemotactic, and growth 
promoting cytokines from EECCs, Ishikawa cells and HUVECs.
Materials and Methods
Ethics approval for human samples
Human eutopic endometrial, ectopic endometriotic tissue samples and plasma samples from 
endometriosis patients and normal eutopic endometrium and plasma samples from women 
without known pathologies were collected and stored after informed consent using approved 
protocols by the Institutional Review Committees at Greenville Health System, Greenville, 
SC, USA, University of North Carolina, Chapel Hill, NC, USA, and Ottawa General 
Hospital, Ottawa, ON, Canada. Normal endometrial tissue and ectopic endometriotic tissue 
sections embedded in paraffin were obtained from the Kingston General Hospital, Kingston, 
ON, Canada with informed consent from the patients. Ethics approval for this study was 
provided by the Health Sciences Research Ethics Board, Queen’s University, Kingston, ON, 
Canada.
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Human endometrium, endometriosis and plasma samples
Human eutopic endometrium, ectopic lesion tissue samples and plasma samples were 
obtained from Greenville Health Systems, Greenville, SC, USA after informed consent from 
patients between ages of 21 and 39 with confirmed endometriosis at the time of laparoscopic 
surgery. Patients received no hormonal therapy for minimal of 3 months prior to 
laparoscopic surgery, and for the duration of participation in the study. Patient 
characteristics including age, BMI, parity, and stage of endometriosis are provided in Table 
1. Eutopic endometrium samples from patients were obtained by Pipelle sampling and 
ectopic lesions were obtained during laparoscopic surgery by excision. Patients were 
consented for additional blood draws at the 2 week post-op visit and at 3 months. Upon 
collection, samples were snap-frozen in liquid nitrogen and stored in −80°C. All plasma 
samples obtained from the patients and healthy women were separated from peripheral 
blood and stored in −80°C.
Multiplex cytokine assay
To assess the concentration of IL-17A in human samples, a Bioplex Pro human cytokine 27-
plex assay (M50-0KCAF0Y, Bio-Rad Laboratories, Mississauga, Canada) was conducted on 
eutopic endometrial and ectopic endometriotic tissue plasma and peritoneal fluid samples 
from women with endometriosis as per kit instructions. Approximately 20 mg of 
endometriotic tissue samples or normal endometrial samples were placed in 1.5 mL 
microcentrifuge tubes containing protease inhibitor (1ul/0.01g of tissue, Sigma-Aldrich, St. 
Louis, MO, USA) with Tissue Extraction Reagent I (100ul/0.01g of tissue, Invitrogen Corp., 
CA, USA). The tissue was homogenized using a rotor-stator homogenizer on ice for 1 
minute and then centrifuged at 18,000 rpm for 15 min at 4°C. The supernatant was collected, 
and protein concentration measured using Pierce BCA Protein Assay Kit as per kit protocol 
(Pierce Biotechnology, IL, USA). The samples were normalized and stored at −80°C until 
later assessment. Plasma samples from healthy subjects were also included as control for the 
plasma samples from endometriosis patients. Briefly, the 96-well cell culture plate was 
coated with assay buffer and magnetic beads, followed by two wash steps using the wash 
buffer. Samples, blanks, and diluted standards were transferred onto the 96-well plate. The 
plate was then incubated in the dark at room temperature on shaker for 30 minutes. After 
three washes using the wash buffer, detection antibody was added to the plate for 30 minutes 
followed by a wash step. The plate was incubated with Streptavidin-Phycoerythrine for 
additional 10 minutes. Finally, the plate was washed before analysis using Bioplex 2000 
Suspension Array System (Bio-Rad Laboratories, Mississauga, ON, Canada).
IL-17A Immunohistochemistry on matched eutopic endometrium and ectopic lesions
Immunohistochemistry was performed on paraffin embedded sections of matched eutopic 
endometrium and ectopic lesion samples obtained from patients. The slides with tissue 
sections cut at 5µm were deparaffinized in Cytrisolv (Fisher Scientific, Ottawa, ON, 
Canada) and subsequent re-hydration in decreasing gradients of ethanol. Heat-induced 
antigen retrieval was conducted using sodium citrate buffer (0.01M, pH 6.0) heated to 95°C 
in a water bath. Endogenous peroxide activity was blocked using 3% H2O2, followed by 
incubation with 1% BSA to block non-specific binding. Sections were incubated with anti-
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human IL-17A rabbit polyclonal antibody (1:250 in 1% BSA/PBS, ab79056, Abcam, Inc, 
Cambridge, MA, USA) or isotype antibody as a negative control. After overnight incubation 
in a humidified chamber at 4°C, sections were incubated with biotinylated secondary 
polyclonal goat anti-rabbit IgG antibody (1:500, Dako, Glostrup, Denmark), stained with 
DAB chromogen (Dako, Glostrup, Denmark) then counter stained with Harris hematoxylin 
(Fisher Scientific, Ottawa, ON, Canada). The sections were dehydrated in increasing 
gradients of ethanol and Citrisolv, coversliped with Permount mounting media (Fisher 
Scientific, Ottawa, ON, Canada), then viewed under the microscope.
Cell culture
Endometrial epithelial carcinoma cells (EECCs, CRL-1671, ATCC, VA, USA) and 
HUVECs (200-05f, Cell applications Inc., San Diego, CA, USA), and Ishikawa Cells 
(99040201-1VL, Sigma-Aldrich, St. Louis, MO, USA) were incubated in a standard cell 
incubator at 37°C with 5% CO2. EECCs and Ishikawa cells were maintained in DMEM 
supplemented with 10% FBS and 1% penicillin and streptomycin (Sigma-Aldrich, St. Louis, 
MO, USA). HUVECs were maintained in All-in-one ready to use Endothelial Cell Growth 
Medium (211–500, Cell Applications, Inc., San Diego, CA, USA). All cell lines were grown 
in T75 cell culture flasks (Corning Inc., NY, USA) up to 70–80% confluence prior to 
experimental use.
WST-1 proliferation assay
EECCs and HUVECs were harvested with Trypsin-EDTA and seeded onto a 96-well tissue 
culture plate (Sarstedt, Inc. Newton, NC, USA) at 1.25×104 cells/well, followed by 
recombinant IL-17A stimulation at different concentrations (1, 5, 25,50, 100 ng/ml, R&D 
Systems, MN, USA) in triplicates. PBS was used as a control. Post 24 hour incubation, 
WST-1 cell proliferation reagent (Roche Diagnostics, Laval, QC, Canada) was added to 
each well for additional 2 hours at 37°C. Using spectrophotometer, absorbance at 450nm 
and 690 nm were measured. Optical density was calculated by subtracting absorbance at 
690nm from 450nm.
Propidium Iodide Cell Cycle analysis
EECCs were plated onto a 6-well plate (Sarstedt, Inc. Newton, NC, USA) at 5×105 cells/
well and were incubated with different concentrations of IL-17A in triplicates (25, 50, 
100ng/ml, R&D systems, MN, USA) and PBS control for 24 hours at 37°C with 5% CO2. 
Post treatment, cells harvested from the plate, pelleted and were fixed in 70% ethanol at 4°C 
overnight. Post fixation and centrifugation to pellet the cells, 1ml of propidium iodide 
(0.04mg/ml, BioShop Canada Inc. Burlington, ON, Canada) and RNase A (0.625mg/ml, 
Sigma-Aldrich, MO, USA) were added to each condition and incubated for 3 hours at 4°C in 
the dark. Beckman Coulter Cytomics FC500 (Beckman Coulter Inc., Mississauga, ON, 
Canada) was used to conduct single-color analysis.
Flow cytometric analysis for IL-17RA
After removal of the growth media from the flask, EECCs and HUVECs were harvested 
using Trypsin-EDTA, pelleted and washed with cell staining buffer (1% BSA, 0.1% sodium 
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azide in PBS). Approximately 1×105 cells were incubated with either mouse anti-human 
IL-17RA antibody conjugated with PE (1:50, FAB177P, R&D systems, MN, USA) or 
Mouse IgG1 isotype control conjugated with PE (1:100, IC002P, R&D systems, MN, USA) 
for 30 minutes in room temperature. Cells were fixed with ice cold 2% Paraformaldehyde in 
PBS for 15 minutes and were kept at 4°C prior to conducting flow cytometric analysis 
(Beckman Coulter Cytomics FC500, Beckman Coulter Inc., Mississauga, ON, Canada).
Cell culture supernatant cytokine analysis from EECCs, Ishikawa cells, and HUVECs 
treated with IL-17A
EECCs and Ishikawa cells were seeded at 5×105 cells/well onto 6 well plate in triplicate 
(Sarstedt, Inc. Newton, NC, USA) and stimulated with different concentrations of IL-17A 
(10, 25, 50, and 100ng/ml, R&D Systems, MN, USA) and PBS as control. HUVECs were 
seeded at 1×105 cells/well onto 6 well plate in triplicate (Sarstedt, Inc. Newton, NC, USA) 
and were incubated with different concentrations of IL-17A (5 and 50 ng/ml, R&D Systems, 
MN, USA) and PBS as control. The cells were incubated for 24 hours in a standard cell 
culture incubator at 37°C with 5% CO2. The conditioned media was collected and were 
analyzed using Human multiplex cytokine analysis (Eve Technologies Corporation, Calgary, 
AL, Canada).
Endothelial cell tubulogenesis assay
Tubulogenesis assay was conducted as per kit protocol (CBA-200, Cell applications Inc., 
San Diego, CA, USA). HUVECs grown to 70–80% confluence in T75 cell culture flask 
(Corning Inc., Corning, NY, USA) were trypsinized, pelleted and seeded onto matrigel 
coated ibidi µ-angiogenesis slide (Ibidi USA Inc., WI, USA) at a density of 5×103 cells/well 
with a complete medium containing different concentrations of IL-17A (1, 5, 50 ng/ml, 
R&D Systems, MN, USA) in triplicate. VEGF (50ng/ml, R&D Systems, MN, USA) and 
PBS was used as a positive and negative control respectively.
Statistical analysis
All statistical analysis was performed using GraphPad Prism 6.0. Ordinary one-way 
ANOVA with Tukey post-hoc test was used to analyze the results of WST-1 proliferation 
assay, supernatant cytokine analysis and tubulogenesis assay. Unpaired t-test was used to 
analyze the results of human tissue and plasma data and flow cytometric data. Data are 
represented as mean ± SD, unless otherwise stated in the figure. Values of p≤0.05 were 
considered statistically significant.
Results
IL-17A concentration in matched tissue sample and plasma sample from women with 
endometriosis is variable compared to healthy controls
In the present study, we evaluated the concentration of IL-17A in tissues and plasma 
samples from patients with or without endometriosis (Fig. 1A–C). Patients were further 
stratified into Stage I, II, III or IV of endometriosis as per the guidelines from American 
Society for Reproductive Medicine. We further grouped Stage I and II patient into Early and 
Stage III and IV into Advanced disease categories. Although statistically non-significant, we 
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observed a trend of increasing IL-17A concentration in the ectopic lesions compared to the 
matched eutopic endometrium obtained from same patients (Fig. 1A). In the plasma 
samples, IL-17A concentration was significantly increased in women with endometriosis 
compared to healthy controls (Fig. 1B). When the matched ectopic lesions and eutopic 
endometrium were stratified by disease severity, we observed persistent increase in IL-17A 
in ectopic lesion samples compared to eutopic endometrium across severity (Fig. 1C). Note 
that the concentration of IL-17A from normal endometrial tissues of disease-free women 
was less than 10pg/mL (n=4, 3.13±1.92 pg/mL, data not shown) and the concentration of 
IL-17A in the peritoneal fluid was negligible (n=24, data not shown).
The plasma concentration of IL-17A diminishes after laparoscopic lesion removal
The systemic concentration of IL-17A in women with endometriosis significantly declined 
after surgical removal of lesions, with mean IL-17A plasma concentrations of 395.1±93.20 
pg/ml pre-surgery and 228.6±78.33 pg/ml, 2 weeks after surgery (Fig. 2).
Immunolocalization of IL-17A in human eutopic endometrium and ectopic endometriotic 
lesions
In the extant literature, there are no reports of IL-17A immunolocalization in the eutopic 
endometrium or peritoneal endometriosis lesions. A single study showed localization of 
IL-17A positive cells in the stroma of an ovarian endometrioma lesion; however, expression 
in peritoneal lesions or matched eutopic endometrium was not examined (28). Here, we 
show the localization of IL-17A positive cells within the stroma and surrounding the 
vasculature in matched eutopic endometrium and ectopic lesion samples from women with 
endometriosis (Fig. 3A and B). Because of the heterogeneous nature of the ectopic lesions, 
we were unable to concretely conclude whether IL-17A staining was increased in ectopic 
lesions as compared to matched eutopic endometrium from same patients.
Interleukin-17 Receptor A is expressed in EECCs and HUVECs
IL-17RA, the primary receptor for IL-17A is reported to be ubiquitously expressed in 
different cell types in mouse (34) and in human (35). Before conducting functional assays 
with IL-17A, we first wanted to establish whether IL-17RA is present on EECCs and 
HUVECs to rationalize their responsiveness to IL-17A. Both EECCs and HUVECs were 
incubated with anti-IL-17RA antibody conjugated with PE at 4°C overnight. Flow 
cytometric analysis revealed that EECCs (Fig. 4A) and HUVECs (Fig. 4B) indeed express 
IL-17RA on the cell surface, which suggests their capacity to specifically respond to IL-17A 
stimulation.
IL-17A does not induce proliferation in EECCs or HUVECs
To investigate whether IL-17A exhibit mitotic effect on epithelial and endothelial cells, we 
incubated EECCs (Fig. 5A) and HUVECs (Fig. 5B) with different concentrations of 
recombinant IL-17A and PBS control. After 24 hours of incubation at 37°C, we did not 
observe any significant difference in proliferative capacity compared to the PBS treated 
wells on either cell line. Therefore, IL-17A does not directly induce mitosis on the EECCs 
or HUVECs in vitro. To determine whether recombinant IL-17A would induce apoptosis in 
Ahn et al. Page 7













EECCs, we performed propidium iodide (PI) flow cytometric assay to determine DNA 
abundance in EECCs treated with IL-17A (25, 50, 100ng/ml) and PBS control. We did not 
observe any differences between IL-17A treated and PBS control groups (data not shown). 
This further strengthens the notion that IL-17A may not directly have proliferative or 
apoptotic effects of epithelial and endothelial cells.
IL-17A induces the production of chemokine and angiogenic cytokines from EECCs
IL-17A is known to induce a variety of cytokines from different tissue types with pleiotropic 
downstream effects. We wanted to investigate the cytokine profile of EECCs when induced 
with varying concentration of IL-17A. Stimulation of EECCs with IL-17A (10, 25, 50, 
100ng/ml) led to the significant increase in the production of angiogenic and chemotactic 
cytokines, namely VEGF, PDGF-AA, CXCL12 and G-CSF (Fig. 6A–D respectively). The 
cytokine profile suggests a potential involvement of IL-17A in mediating neo-angiogenesis 
and recruitment of lymphocytes and bone-marrow derived cells to the site of lesion 
development. In earlier studies, we (31) and others (32) showed that CXCL12 contributes to 
the recruitment of endothelial progenitor cells at the endometriotic lesions and aid neo-
angiogenesis.
IL-17A induces the production of pro-inflammatory cytokines and chemokines from 
HUVECs
Similar to EECCs, different concentrations of IL-17A (5 and 50ng/ml) induced the 
production of pro-inflammatory cytokines and chemokines from HUVECs, namely IL-1α, 
CXCL1, IL-6 and CX3CL1 (Fig. 7A–D, respectively) in a dose dependent fashion. These 
cytokines are well known for their potent pro-inflammatory actions. This data suggests the 
ability of IL-17A to regulate the expression of pro-inflammatory, angiogenic cytokines and 
chemokines in the peritoneal environment.
IL-17A induces the production of pro-inflammatory cytokines from Ishikawa cells
In the endometriosis literature, EECCs and Ishikawa cells have been widely used to 
understand molecular mechanisms involved in the pathogenesis of endometriosis. We 
wanted to establish how Ishikawa cells would respond to IL-17A stimulation. Here we 
report that stimulation of Ishikawa cells with different concentrations of IL-17A lead to 
increased expression of pro-inflammatory and chemotactic cytokines in a dose dependent 
manner, namely IL-1β, IL-8, IL-9, and CCL11. (Fig. 8A–D, respectively). It is well 
described in literature that IL-1β, IL-8, and CCL11 are increased in concentration in the 
peritoneal fluid of women with endometriosis and are thought to contribute to the 
pathogenesis of the disease.
IL-17A promotes tubulogenesis from HUVECs in a dose dependent fashion
The endothelial tube formation assay is a fast, quantifiable method for measuring in vitro 
angiogenesis and is a standard method used to investigate the effects of an angiogenic 
stimulant or inhibitor on endothelial cells. To investigate whether IL-17A can induce direct 
tubulogenesis, HUVECs seeded on a coat of matrigel were treated with different 
concentrations of IL-17A in complete endothelial cell growth medium for 16 hours at 37°C 
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prior to the analysis of tubulogenesis, unlike other methods where endothelial cells are 
serum starved prior to tubulogenesis assay (26). Our data showed that IL-17A induces 
tubulogenesis of HUVECs on matrigel in a dose dependent manner (Fig. 9A and B), 
suggesting that IL-17A is capable of inducing direct tubulogenesis of endothelial cells in 
vitro.
Discussion
Interleukin (IL)-17A has been implicated in several chronic, inflammatory and autoimmune 
disorders; however its association with the pathogenesis of endometriosis has not previously 
been well described. We provide the first evidence that endometriotic lesions produce 
IL-17A protein in variable amounts depending on the stage of the disease. Traditionally, 
IL-17A was thought to be produced only by Th17 cells; however, recent reports suggest that 
variety of cell types produce IL-17A including stromal cells, fibroblasts, and endothelial 
cells (34). Immunohistochemical analysis provides further evidence that IL-17A is 
expressed by the endometriotic lesions, but the complexity and heterogeneous nature of the 
endometriotic lesions precludes identification of the specific cell types. Strikingly, we 
demonstrated significant decline in plasma concentration of IL-17A after surgical removal 
of endometriotic lesions. These findings strongly suggest that IL-17A may be a contributory 
factor to the inflammatory peritoneal milieu associated with endometriosis. The association 
between the removal of the lesion and decrease in IL-17A further suggest the role of the 
ectopic lesion as a potential reservoir of IL-17A, or the removal of the lesion simply leads to 
the diminishment in the pro-inflammatory environment, where IL-17A is a component that 
mediates the pro-inflammatory status. It is likely that, with the removal of the lesion, the 
tissue resident Th17 cells, and other potential producers of IL-17A are also removed, 
thereby contributing to the significantly lowered concentration of IL-17A detected in the 
peripheral blood.
The source of IL-17A can be speculated by analyzing the data available on the peritoneal 
fluid of women with endometriosis. If the main source of IL-17A is from peritoneal fluid 
resident immune cells, the concentration of IL-17A in the peritoneal fluid will be elevated. 
Zhang et al. (29) documented elevated concentration of IL-17A in the peritoneal fluid in 
minimal or mild endometriosis as compared to severe disease, ranging between 5–6 pg/ml. 
This study did not find a significant difference in the peritoneal fluid concentration of 
IL-17A between women with endometriosis and without disease. On the contrary, we could 
not detect measurable levels of IL-17A in the peritoneal fluid from women with 
endometriosis (n=24, data not shown). Since we show that the removal of the lesion led to 
the significant decrease of IL-17A in the plasma, the effect of removal likely involves 
changes within the systemic immune system. It is possible that, unlike other 
proinflammatory cytokines, IL-17A is primarily produced by tissue resident immune cells, 
and as such may not be detectable in the peritoneal fluid. To clarify these findings, we need 
to establish whether IL-17A positive, tissue-resident immune cells in women with 
endometriosis are indeed the source of IL-17A in this disease.
Endometriosis is a disease mediated by inflammatory and angiogenic peritoneal 
environment. Using cell lines well established in the endometriosis literature, we document 
Ahn et al. Page 9













the unique cytokine signatures induced by IL-17A in EECCs, Ishikawa cells and HUVECs. 
In particular, IL-17A induced production of chemotactic and angiogenic factors including 
G-CSF, VEGF, CXCL12, and IL-8 from EECCs and Ishikawa cells. In addition, IL-17A 
induced the production of chemotactic and pro-inflammatory cytokines such as CXCL1, 
CX3CL1 and IL-6 from HUVECs. Taken together, our data suggests that IL-17A may be 
involved in the orchestration of a paracrine network of cytokines between the adjacent cells 
that leads to the promotion of angiogenesis and inflammation in the peritoneal cavity. 
Specifically, our data suggests that IL-17A has the potential to enhance vascularization of 
the lesion through VEGF and IL-8 mediated pathways. Evidence for de novo vasculogenesis 
at endometriosis lesions has been previously suggested by a report of the recruitment of 
EPCs to the lesion site via a CXCL12 mediated pathway (36).
IL-17A may also play a crucial role in the promotion of inflammation via the recruitment of 
immune cells by inducing the production of chemokines such as G-CSF, CCL11, CXCL1 
and CX3CL1 from the endometriotic lesion. For instance, IL-17A-induced CX3CL1 may 
play a critical role in the mobilization of pro-inflammatory monocytes and other immune 
cells into the lesion. CX3CL1 is both an adhesion molecule and chemotactic cytokine for T 
cells and monocytes that acts by adhering and immobilizing the cells to the endothelial cell 
surface (37, 38), and whose production by HUVECs can be induced by IFN-γ (39). Thus, 
IL-17A may not only initiate the process of inflammation in endometriosis, but also sustain 
it through the indirect mobilization of pro-inflammatory immune cells by inducing the 
production CX3CL1 from the endothelial cells of the lesion. Taken together, the data 
suggests a potential therapeutic effect of IL-17A blockade in endometriosis. Decoding the 
paracrine network established between different cell types in the lesion will enhance our 
understanding of the mechanisms employed by IL-17A in establishing the pro-inflammatory 
and pro-angiogenic environment in endometriosis.
Current research suggests inherent molecular differences in eutopic endometrium of women 
with endometriosis that allows the menstrual exudate to escape immunesurveillance and 
develop into ectopic foci in the pelvic cavity. In addition, the immune system of women 
with endometriosis behaves curiously in the presence of endometrial fragments. As such, the 
pathogenesis of endometriosis may be two-fold: women with endometriosis have 
endometrial cell dysfunction that stimulate aberrant innate and adaptive immune responses 
towards the endometrial fragments found in ectopic locations, allowing for the fragments to 
survive and implant to grow into endometriosis. These immune cells are not only producing 
increased amount of pro-inflammatory and growth promoting cytokines, but also exhibit 
diminished cytotoxicity/adaptive responses towards the fragments. Such immune cell 
activity is reflected in the inflammatory milieu known to be associated with the peritoneal 
environment of endometriosis. We hypothesize that the immune cells would be the major 
producer of IL-17A, which trigger other cells in the vicinity that express its receptor to make 
cytokine that are typically found in endometriosis environment.
In literature, IL-17A is shown to promote direct endothelial cell tubulogenesis in vitro (26, 
40). Here, we also show direct effect of IL-17A in promoting tubulogenesis of HUVECs. 
Typically other studies use serum starved media on matrigel to study the angiogenic effect 
of IL-17A. In this study, we opted to use complete growth media supplemented with growth 
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factors and FBS. The rational for using the complete endothelial cell growth media for our 
experiment is to achieve the similar angiogenic environment of peritoneal fluid that bathes 
endometriotic lesions in the peritoneal cavity. This allows us to elucidate if the presence of 
IL-17A, in addition to other growth factors, would elicit an additive effect in driving 
tubulogenesis. This method also allows our data to be translatable to in vivo situation as 
endometriotic lesions are exposed to growth promoting cytokines in the peritoneal fluid.
Overall, the limitation of the current study is inherent in endometriosis research in general. 
To conduct proper interpretation and comparison of data, the tissue samples between 
patients and controls must be matched in menstrual stage, disease stage, and age of the 
individual. In addition, the medical history of individuals and therapeutic regimens needs to 
be taken into account to consider the effect of estrogen and progesterone on the disease 
state. The analysis is further complicated by the complexity of endometriosis which comes 
in multiple stages and phenotypes. Furthermore, only old-world primate species, including 
humans, develop spontaneous endometriosis, increasing the complexity of using animal 
models. Finally, both the diagnosis and staging of endometriosis depends upon surgery, 
making it difficult to study and establish true control subjects. For all these reasons, 
understanding of the disease remains rudimentary and simple classifications lack biological 
uniformity. As such, wide variations between studies are observed, including cytokine 
concentrations in the peritoneal fluid. Despite these issues, this study showing the significant 
decrease in the plasma concentration of IL-17A post laparoscopic removal of the 
endometriotic lesion, coupled with the ability of IL-17A to induce a myriad of cytokines 
from stromal, epithelial and endothelial cells strongly suggests its potential contribution to 
endometriosis pathogenesis. Further research is required to identify the source and location 
of IL-17A in endometriosis to advance our understanding of the specific role(s) IL-17A may 
play in the pathogenesis of endometriosis.
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IL-17A expression in tissue and plasma samples. (A) Matched eutopic endometrium (n=14, 
23.0±3.84pg/ml) and ectopic lesions (n=14, 29.77±1.97pg/ml) (B) Plasma samples from 
women without (n=7, 72.90±18.94pg/ml) and with (n=17, 499.4±116.4pg/ml) 
endometriosis. IL-17A levels were significantly higher in women with endometriosis 
compared to healthy controls (*p<0.05). (C) IL-17A concentration in matched eutopic 
endometrium and ectopic lesions distributed by disease severity following ASRM staging 
criteria (early denotes Stages I-II, and advanced denotes Stages III-IV). All data are 
represented as mean ± SEM.
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IL-17A concentration in plasma of women (n=10) undergoing laparoscopy surgery for the 
removal of endometriosis. IL-17A concentration was measured from the patient prior to 
undergoing surgery and 2 weeks post-surgical visit to the clinic. The concentration of 
IL-17A diminishes significantly in the peripheral blood of women with endometriosis after 
lesion is removed (*p=0.0016).
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IL-17A positive cells are detected in the matched eutopic (A) and ectopic lesion (B) samples 
from women with endometriosis. Immunohistochemistry images are representative of 5 
matched tissue samples immunostained with anti-human IL-17A. 200× magnification with 
digitally magnified inlet; scale bar represents 100µm.
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IL-17RA is expressed on EECCs and HUVECs. EECCs (A) and HUVECs (B) were stained 
with either PE conjugated mouse anti-human IL-17RA or PE conjugated Mouse IgG isotype 
control in room temperature. On average 65.2±3.9% of EECCs stained for IL-17RA whereas 
58.1±14.6% cell surface staining was seen for HUVECs. Representative of three separate 
experiments. *p<0.05 compared to isotype.
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WST-1 proliferation assay indicate that IL-17A does not induce proliferation of EECCs and 
HUVECs in vitro. (A) EECCs were treated with different concentrations of IL-17A (1, 5, 
25, 50 and 100 ng/ml) or PBS control to assess the effect of IL-17A on proliferation. (B) 
HUVECs were treated with different concentrations of IL-17A (1, 5, 25, 50 and 100 ng/ml) 
or PBS control to assess the effect of IL-17A on proliferation. VEGF (10, 20, 50 ng/ml) was 
used as a positive control. Three separate WST-1 proliferation assay were conducted on both 
(A) and (B) as per standard protocol.
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IL-17A induces production of chemokine and angiogenic cytokines from EECCs. 
Endometrial epithelial carcinoma cells (EECCs) were plated onto a 96-well cell culture plate 
in triplicate at a density of 5×105cells/well and incubated with different concentrations of 
IL-17A (10, 25, 50, 100ng/mL) for 24 hours at 37°C with 5% CO2. The conditioned 
supernatants of EECCs were collected and screened for cytokine expression from which 
PDGF-AA, VEGF, CXCL12 and G-CSF showed statistical significance. *p < 0.05 
compared with PBS.
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IL-17A induces the production of pro-inflammatory cytokines and chemokines from 
HUVECs in a dose dependent manner. HUVECs were plated onto a 6-well plate in triplicate 
at a density of 1×105 cells/plate and were incubated with different concentrations of IL-17A 
(5 and 50 ng/ml) for 24 hours in a standard cell culture incubator at 37°C with 5% CO2. 
Conditioned supernatants were collected and screened for cytokine expression from which 
IL-1α, CXCL1, IL-6, CX3CL1, and G-CSF (A-E, respectively) showed statistical 
significance. *p<0.05 compared with PBS.
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IL-17A induces production of chemokine, angiogenic and pro-inflammatory cytokines from 
Ishikawa cells. Ishikawa cells were plated onto a 96-well cell culture plate in triplicate at a 
density of 5×105cells/well and incubated with different concentrations of IL-17A (5 and 50 
ng/mL) or PBS control for 24 hours at 37°C with 5% CO2. The conditioned supernatants of 
each treatment were collected and screened for cytokine expression from which IL-1β, IL-8, 
IL-9 and CCL11 showed statistical significance. *p < 0.05 compared with PBS.
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IL-17A promotes in vitro tubulogenesis in HUVECs. (A) HUVECs were plated on Matrigel 
at 5×103 cells/well using Ibidi µ-slide angiogenesis plate (Cat. #81506) in triplicate per 
treatment. VEGF (50ng/ml) and PBS were used as a positive and negative control, 
respectively. Scale bar represents 10µm. 150× magnification using a confocal microscope 
(Quorum Wave Effects Spinning Disc Confocal, Queen’s University Cancer Research 
Institute Imaging Facility) (B) Total length of branches in the field of image was measured 
using ImageJ Angiogenesis Analyzer Macro with HUVECs phase contrast setting. *p<0.05 
compared with PBS.
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Table 1
Endometriosis study patients and healthy control subject characteristics
Parameters Endometriosis Control
Number of patients participated in study n = 24a n = 10
Age (years) 26.7 ± 7.6 27.3 ± 5.5
BMI (kg/m2) 25.3 ± 6.1 22.5 ± 2.4
Parity 25%b 20%c
Stage of endometriosis
Stages I–II n = 16
Stages III–IV n = 8
a
patients on oral contraceptive therapy, progestins, gonadotrophin releasing hormone agonist/antagonist, aromatase inhibitors, or any other 
medications used towards the management of endometriosis during the study were excluded.
b
6 out of 24 endometriosis patients were parity 1 ; all other patients were nulliparous.
c
2 out of 10 control subjects were parity 1; all other control subjects were nulliparous.
± Standard deviation
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